Human secondary lymphoid-tissue chemokine,SLC ELISA Kit

Code CSB-E04521h
Size 96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
chemokine (C-C motif) ligand 21
Alternative Names
6Ckine ELISA Kit; Beta chemokine exodus 2 ELISA Kit; Beta-chemokine exodus-2 ELISA Kit; C C motif chemokine ligand 21 ELISA Kit; C-C motif chemokine 21 ELISA Kit; CCL21 ELISA Kit; CCL21_HUMAN ELISA Kit; Chemokine (C-C motif) ligand 21 ELISA Kit; Chemokine CC motif ligand 21 ELISA Kit; CKb9 ELISA Kit; ECL ELISA Kit; Efficient Chemoattractant for Lymphocytes ELISA Kit; SCYA21 ELISA Kit; Secondary lymphoid tissue chemokine ELISA Kit; Secondary lymphoid-tissue chemokine ELISA Kit; SLC ELISA Kit; Small inducible cytokine A21 ELISA Kit; Small inducible cytokine subfamily A (Cys-Cys); member 21 ELISA Kit; Small-inducible cytokine A21 ELISA Kit; TCA4 ELISA Kit; UNQ784/PRO1600 ELISA Kit
Abbreviation
CCL21
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma
Detection Range
78 pg/mL-5000 pg/mL
Sensitivity
19.5 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human SLC/CCL21 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 92
Range % 89-98
1:2 Average % 103
Range % 95-107
1:4 Average % 91
Range % 86-98
1:8 Average % 93
Range % 87-98
Recovery
The recovery of human SLC/CCL21 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 97 91-102
EDTA plasma (n=4) 86 82-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
5000 2.983 2.991 2.987 2.844
2500 2.217 2.183 2.200 2.057
1250 1.437 1.489 1.463 1.320
625 0.890 0.883 0.887 0.744
312.5 0.558 0.576 0.567 0.424
156 0.399 0.382 0.391 0.248
78 0.257 0.252 0.255 0.112
0 0.142 0.143 0.143  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The product CSB-E04521h is a sandwich ELISA kit developed to measure concentrations of human secondary lymphoid-tissue chemokine (SLC) in serum or plasma. This assay uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of SLC in samples. The color intensity is measured at 450 nm via a microplate reader.

SLC, also called CCL21, is a chemokine that mediates the recruitment of multiple leukocyte subsets through CCR7-mediated signaling during the steady-state and inflammation. It plays a vital role in the homing and localization of immune cells to lymphoid tissues. CCL21 is also involved in priming adaptive immunity via governing egress of dendritic cells (DCs) from barrier tissues and T cell entry and positioning in secondary lymphoid organs. CCL21/CCR7 signaling promotes growth and metastasis of many tumor types including melanomas, breast, thyroid, colon, head, and neck cancers.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.
Gene References into Functions
  1. High CCL21 expression is associated with urinary bladder cancer metastasis. PMID: 28534984
  2. Significant associations between the CCL21 rs2812378 G;A polymorphism and rheumatoid arthritis risk were observed in the total population, as well as in subgroup Caucasian population. PMID: 28799100
  3. Low CCL21 expression was a potential independent adverse prognostic biomarker for overall survival and progression-free survival for metastatic renal cell carcinoma patients treated with targeted therapy. PMID: 27783999
  4. these results demonstrated that CCL21/CCR7 may activate EMT in lung cancer cells via the ERK1/2 signaling pathway. PMID: 28487957
  5. CCL21/CCR7 interaction was shown to allow NK cell adhesion to endothelial cells (ECs) and its reduction by hypoxia. PMID: 28416768
  6. These data show that CCR7-CCL19/CCL21 axis facilitates retention CD4(+) T lymphocytes at the site of collateral artery remodeling, which is essential for effective arteriogenesis. PMID: 28275068
  7. CCL21 correlated significantly with Bladder Pain Syndrome: gene expression in bladder biopsies of patients with Bladder Pain Syndrome was increased in the patients and correlated with clinical profiles. PMID: 26965559
  8. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells. PMID: 27157859
  9. plasmin cleaves surface-bound CCL21 to release the C-terminal peptide responsible for CCL21 binding to glycosaminoglycans on the extracellular matrix and cell surfaces, thereby generating the soluble form. PMID: 27301418
  10. the white pulp regions of ME7-infected spleens were smaller, and contained markedly diminished T zones, as compared to control spleens. Although lymphoid tissue inducer cells were not affected, the expression of both CCL19 and CCL21 was decreased. PMID: 27021907
  11. Taken together, these results suggest that SERCA2 contributes to the migration of CCL21-activated Dendritic Cells as an important feature of the adaptive immune response and provide novel insights regarding the role of SERCA2 in Dendritic Cells functions. PMID: 27538371
  12. An expanded lymphatic network is capable of enhanced chemoattractant CCL21 production, and lymphangiogenesis will facilitate initial lymph formation favoring increased clearance of fluid in situations of augmented fluid filtration. PMID: 28935759
  13. Results provide evidence for an association between an increase level of CCL21 and IP-10 in the blood and pulmonary involvement in systemic lupus erythematosus patients. PMID: 27614982
  14. Gata1-KO(DC) DCs have reduced polysialic acid levels on their surface, which is a known determinant for the proper migration of DCs toward CCL21. PMID: 27815426
  15. CCL21 and CXCL13 levels are increased in the minor salivary glands of patients with Sjogren's syndrome. PMID: 27782867
  16. CCL21/CCR7 interaction contributes to the time-dependent proliferation of PTC cells by upregulating cyclin A, cyclin B1 and cyclin-dependent kinase 1 (CDK1) expression via the extracellular signal-regulated kinase (ERK) pathway associated with iodine. PMID: 27574129
  17. CCL21 can facilitate chemoresistance and stem cell property of colorectal cancer cells via the upregulation of P-gp, Bmi-1, Nanog, and OCT-4 through AKT/GSK-3beta/Snail signals. PMID: 27057280
  18. CCL21/CCR7 induce VEGF-D up-regulation and promote lymphangiogenesis via ERK/Akt pathway in lung cancer. PMID: 26884842
  19. Our findings suggested that MUC1 plays an important role in CCL21-CCR7-induced lymphatic metastasis and may serve as a therapeutic target in esophageal squamous cell carcinoma . PMID: 26667143
  20. TGF-beta1 promoted CCL21 expression in lymphatic endothelial cells. CCL21 acted in a paracrine fashion to mediate chemotactic migration of EMT cells toward lymphatic endothelial cells. PMID: 25961925
  21. increased expression in mononuclear inflammatory cells isolated from the brain during active stage of experimental autoimmune encephalomyelitis PMID: 25957582
  22. The chemotactic interaction between CCR7 and its ligand, CCL21, may be a critical event during progression in pancreatic cancer PMID: 21594558
  23. CCL21 gene SNP (rs951005) might confer genetic predisposition to polymyositis patients or such patients with interstitial lung disease in a Chinese Han population. PMID: 26320593
  24. over-expression of CCL21 could increased the expressions of antigen presentation-related genes in CK8/18 TECs in MG patients PMID: 26146068
  25. Priming by CCL21 restricts lateral mobility of the adhesion receptor LFA-1 and restores adhesion to ICAM-1 nanoaggregates on human mature dendritic cells. PMID: 24945611
  26. CCL21/CCR7 pathway activates signallings to up-regulate Slug pathway, leading to the occurrence of epithelial-mesenchymal transition process in human chondrosarcoma PMID: 25556164
  27. These results reveal that CCR7 and VEGF-C display a significant crosstalk and suggest a novel role of the CCL21/CCR7 chemokine axis in the promotion of breast cancer-induced lymphangiogenesis. PMID: 25744065
  28. CCL21 promotes the metastasis of pancreatic cancer via epithelial-mesenchymal transition. PMID: 25575049
  29. Modulation of the chemokines CCL19 and CCL21 represents a potent immunoregulatory treatment approach, and thus represents a novel therapeutic target to stabilize atherosclerotic lesions. PMID: 25473269
  30. CCL21/CCR7 interactions might be involved in the response to pressure overload secondary to aortic stenosis. PMID: 25398010
  31. CCL21 and CCL19 were significantly increased in serum from ankylosing spondylitis patients. PMID: 25260647
  32. overexpressed in myasthenia gravis thymus PMID: 24393484
  33. Studied expression of CCR7 and EMT markers in the primary breast carcinoma tissues from patients who underwent radical mastectomy. and investigated whether CCL21/CCR7 induces EMT process during mediating cancer cell invasion or migration in vitro. PMID: 25142946
  34. CCL21 was shown to be involved in the induction of ulcerative colitis. Suppression of CCL21 expression decreased damage induced from ulcerative colitis, indicating that CCL21 targeted therapy might be an effective treatment for this disease PMID: 24841666
  35. CCL21 rs2812377 was associated with coronary artery disease in a Chinese Han population. PMID: 24990231
  36. CCL21 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
  37. Although CCL21 levels are elevated, no CCL21-positive cells are observed in patients with eosinophilic pneumonia. PMID: 24111618
  38. CCL21 expression was increased in hyperplastic myasthenia gravis thymuses. PMID: 24556356
  39. these data suggested an important role of the lymphoid-endothelium-associated chemokine, CCL21, on dendritic cells in the induction of cytotoxic T lymphocytes responses. PMID: 24383579
  40. Elevated serum CCL21 correlates with opsoclonus-myoclonus syndrome severity and duration in pediatric opsoclonus-myoclonus syndrome. PMID: 23764550
  41. CCL21 expression was found to be an independent prognostic biomarker for CRC. PMID: 23760102
  42. In amnion epithelial cells exposed to zinc ferrite nanoparticles there is an increase in CCL21 activation; in situ nanoparticles induce oxidative stress, alterations in cellular membrane and DNA strand breaks. PMID: 24035972
  43. Results suggest that the CCL21/CCR7 signaling pathway is involved in renal fibrosis in kidney transplant patients. PMID: 23498789
  44. CCL21 attenuates HSV-induced inflammation through up-regulation of CD8+ memory cells. PMID: 22884357
  45. CCL21 is a mediator of rheumatoid arthritis angiogenesis. PMID: 22392503
  46. oxLDL induces an in vitro downregulation of CCR7 and CCL21, which may play a role in the reduction of dendritic cell migration from the plaques PMID: 22619482
  47. High serum levels of CCL21 are independently associated with mortality in chronic and acute post-myocardial infarction heart failure. PMID: 22427939
  48. CCL21/CCR7 prevents apoptosis by upregulating the expression of bcl-2 and by downregulating the expression of bax and caspase-3 potentially via the ERK pathway in non-small cell lung cancer cell lines PMID: 22438908
  49. CCL21 was more localized to chondrocytes and meniscal cells during the development of osteoarthritis in mice. PMID: 21972019
  50. CCL21 structure solved by nuclear magnetic resonance (NMR) contains a conserved chemokine domain followed by an extended, unstructured C-terminus that is not typical of most other chemokines. PMID: 22221265

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Intercrine beta (chemokine CC) family
Tissue Specificity
Highly expressed in high endothelial venules of lymph nodes, spleen and appendix. Intermediate levels found in small intestine, thyroid gland and trachea. Low level expression in thymus, bone marrow, liver, and pancreas. Also found in tonsil, fetal heart
Database Links

HGNC: 10620

OMIM: 602737

KEGG: hsa:6366

STRING: 9606.ENSP00000259607

UniGene: Hs.57907

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X